Researchers find new biomarker for breast cancer

by Austrian Science Fund (FWF)Mammograms showing a normal breast (left) and a breast with cancer (right). Credit: Public DomainWith the support of the FWF, an oncologist found a biomarker for bre

Updated on: March 01,2024 13

Researchers find new biomarker for breast cancer

by Austrian Science Fund (FWF)Mammograms showing a normal breast (left) and a breast with cancer (right). Credit: Public DomainWith the support of the FWF, an oncologist found a biomarker for bre

Updated on:March 01,2024 13

Researchers publish action plan to address appendiceal cancer enigmas

Updated on: April 29,2025 0

Researchers publish action plan to address appendiceal cancer enigmas

Updated on:April 29,2025 0

Researchers identify women with twice the risk of cancer in both breasts

by Mayo ClinicCumulative incidence of CBC risk in PV carriers. Cumulative incidence plots for first contralateral breast cancers after primary breast cancer. Cumulative incidence is plotted again

Updated on: February 18,2024 10

Researchers identify women with twice the risk of cancer in both breasts

by Mayo ClinicCumulative incidence of CBC risk in PV carriers. Cumulative incidence plots for first contralateral breast cancers after primary breast cancer. Cumulative incidence is plotted again

Updated on:February 18,2024 10

Why a promising breast cancer drug doesn't work—and how to improve it

by Katherine Fenz,Rockefeller UniversityER-mediated transcriptional resistance to BD inhibition. Credit:Nature Structural & Molecular Biology(2024). DOI: 10.1038/s41594-024-01384

Updated on: September 28,2024 0

Why a promising breast cancer drug doesn't work—and how to improve it

by Katherine Fenz,Rockefeller UniversityER-mediated transcriptional resistance to BD inhibition. Credit:Nature Structural & Molecular Biology(2024). DOI: 10.1038/s41594-024-01384

Updated on:September 28,2024 0

Reversing chemotherapy resistance in pancreatic cancer

byStanford UniversityCredit: CC0 Public DomainPancreatic cancer is a particularly aggressive and difficult-to-treat cancer, in part because it is often resistant to chemotherapy. Now, researcher

Updated on: July 05,2024 0

Reversing chemotherapy resistance in pancreatic cancer

byStanford UniversityCredit: CC0 Public DomainPancreatic cancer is a particularly aggressive and difficult-to-treat cancer, in part because it is often resistant to chemotherapy. Now, researcher

Updated on:July 05,2024 0

Poor oral health linked to a 75% increase in liver cancer risk, new study finds

by SAGE PublicationsCredit: CC0 Public DomainThe study, by researchers at Queen's University Belfast, analysed a large cohort of over 469,000 people in the UK, investigated the association be

Updated on: May 21,2024 3

Poor oral health linked to a 75% increase in liver cancer risk, new study finds

by SAGE PublicationsCredit: CC0 Public DomainThe study, by researchers at Queen's University Belfast, analysed a large cohort of over 469,000 people in the UK, investigated the association be

Updated on:May 21,2024 3

Trial: Standard chemoradiation superior to de-intensification approaches for HPV-related oropharyngeal cancer

byAmerican Society for Radiation OncologyCredit: Unsplash/CC0 Public DomainResearchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal canc

Updated on: October 22,2024 0

Trial: Standard chemoradiation superior to de-intensification approaches for HPV-related oropharyngeal cancer

byAmerican Society for Radiation OncologyCredit: Unsplash/CC0 Public DomainResearchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal canc

Updated on:October 22,2024 0

T-cell interactions vary between tumor microenvironments

by Melissa Rohman,Northwestern UniversityShown is a p-STAT3- non-reactive astrocyte (white arrow) in close proximity to a CD3+p-STAT3- T cell (blue arrow) and a CD163+p-STAT3- macrophage (red ar

Updated on: April 01,2024 0

T-cell interactions vary between tumor microenvironments

by Melissa Rohman,Northwestern UniversityShown is a p-STAT3- non-reactive astrocyte (white arrow) in close proximity to a CD3+p-STAT3- T cell (blue arrow) and a CD163+p-STAT3- macrophage (red ar

Updated on:April 01,2024 0

Specialized immune cells carry potential for new cancer immunotherapies

byLeiden UniversityTumor-infiltrating Vδ1 and Vδ3 T cell subsets display hallmarks of cytotoxic activity in MMR-d colon cancers. a, UMAP embedding showing the clustering of γδ T cells (n = 4,442

Updated on: January 23,2024 11

Specialized immune cells carry potential for new cancer immunotherapies

byLeiden UniversityTumor-infiltrating Vδ1 and Vδ3 T cell subsets display hallmarks of cytotoxic activity in MMR-d colon cancers. a, UMAP embedding showing the clustering of γδ T cells (n = 4,442

Updated on:January 23,2024 11

Researchers map intricacies of lung cancer in one of their own

by Krista Conger,Stanford University Medical CenterJames Spudich (left) made an unusual offer last fall to colleague Mark Krasnow: a sample of a lung tumor that was to be removed from Spudich th

Updated on: June 04,2024 5

Researchers map intricacies of lung cancer in one of their own

by Krista Conger,Stanford University Medical CenterJames Spudich (left) made an unusual offer last fall to colleague Mark Krasnow: a sample of a lung tumor that was to be removed from Spudich th

Updated on:June 04,2024 5

Prostate cancer: Can AI help to avoid unnecessary biopsies?

byGerman Cancer Research CenterRisk stratification example from the test cohort: a 66-year-old male presents with negative DRE, PSA elevation to 6.2 ng/mL, prostate volume of 82.5 mL, and PSAD o

Updated on: August 27,2024 0

Prostate cancer: Can AI help to avoid unnecessary biopsies?

byGerman Cancer Research CenterRisk stratification example from the test cohort: a 66-year-old male presents with negative DRE, PSA elevation to 6.2 ng/mL, prostate volume of 82.5 mL, and PSAD o

Updated on:August 27,2024 0

Epigenetic mechanism associated with clinical outcome and therapeutic vulnerability in liver cancer

by Josep Carreras Leukaemia Research InstituteNSUN7 epigenetic loss occurs in human primary HCC tumors in association with worse clinical outcome. (A) Percentage of NSUN7 methylation in the TCGA

Updated on: February 18,2024 19

Epigenetic mechanism associated with clinical outcome and therapeutic vulnerability in liver cancer

by Josep Carreras Leukaemia Research InstituteNSUN7 epigenetic loss occurs in human primary HCC tumors in association with worse clinical outcome. (A) Percentage of NSUN7 methylation in the TCGA

Updated on:February 18,2024 19